Prognose
| Køb |
1 |
| Behold |
2 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
DiaSorin share falls after UBS downgrade and increased competitive pressure
DiaSorin’s stock fell 3.8% to €73.68 after UBS cut its rating from "neutral" to "sell" and reduced the price target by about 17% to €55. The bank pointed to rising competitive pressure, political headwinds from China and doubts that the new molecular diagnostics platform Liaison Nes will achieve the expected market shares. UBS sees 2026 EBIT 4–6% below consensus and criticizes a valuation premium versus peers such as bioMérieux. » Mere på de.investing.com
DiaSorin reports revenue decline in Q1, confirms full-year guidance
DiaSorin recorded a revenue decline in the first quarter of 2026 (constant -3%, nominal -8%) and an EPS of $0.85, which missed analysts’ estimates, weighed down by negative currency effects, pricing pressure in China and a mild flu season. Despite the setbacks, management is maintaining the full-year guidance and expects currency-adjusted revenue growth of 5–6% and an adjusted EBITDA margin of 32–33%, supported by investments in the LIAISON NES and PLEX platforms. Investors will be watching the FDA decision on the GI panel, the market launch of LIAISON NES and developments in China closely. » Mere på de.investing.com
DiaSorin confirms stable growth for 2025 and expects acceleration in 2026
DiaSorin reports 2025 revenue of €1,195m (+1%) and maintains an adjusted EBITDA margin of 33%. Excluding COVID-related sales, core business grew by 5%, driven by immunodiagnostics (€785m, +7% ex‑COVID) and a strong performance in North America, while China remained pressured by VBP implementation and reimbursement cuts. Molecular diagnostics showed mixed trends; automated multiplexing softened, targeted molecular diagnostics grew strongly, and new panels as well as the LIAISON PLEX/NES launches are expected to boost 2026. For 2026 management forecasts revenue growth of 5–6% at constant exchange rates and an adjusted EBITDA margin of around 32–33%, with acceleration expected in the second half of the year. » Mere på de.investing.com
CFO change: Piergiorgio Pedron leaves DiaSorin for Nexi – shares fall
DiaSorin’s stock fell 2.3% after group CFO Piergiorgio Pedron announced he will move to Nexi on 31 March 2026. Alberto Donati will become the new CFO on 1 April 2026; he brings more than 14 years of experience at DiaSorin and most recently led the finance team at Luminex. Analysts view Donati’s appointment as support for the growth strategy in molecular diagnostics, while investors have reacted negatively to the leadership change in the short term. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalI 2026 har DiaSorin allerede udloddet 1,30 € i udbytte. Den seneste udlodning fandt sted i maj.
Virksomhedstal
I det seneste kvartal havde DiaSorin en omsætning på 601,1 mio. € og et nettoresultat på 83,87 mio. €
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 601,1 mio. | 96,26 % |
| Bruttofortjeneste | 389,42 mio. | 92,86 % |
| Nettoresultat | 83,87 mio. | 76,94 % |
| EBITDA | 198,12 mio. | 42,31 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 4,15 mia. € |
Antal aktier | 49,5 mio. |
Højeste/laveste i 52 uger | 83,84 € - 60,60 € |
Udbytteafkast | 1,57 % |
Udbytte TTM | 1,30 € |
Beta | 0,66 |
P/E (PE Ratio) | 25,17 |
PEG (PEG Ratio) | -0,94 |
K/I (PB Ratio) | 3,18 |
P/S (PS Ratio) | 2,29 |
Virksomhedsprofil
DiaSorin S.p.A. udvikler, fremstiller og distribuerer immundiagnostiske og molekylærdiagnostiske testkits i Europa, Afrika, Nordamerika, Mellem- og Sydamerika, Asien-Stillehavsregionen og Kina. Virksomheden tilbyder forskellige immundiagnostiske LIAISON-platforme, herunder LIAISON XS, LIAISON XL og LIAISON XL LAS; og en molekylærdiagnostisk platform bestående af LIAISON MDX, der anvendes til amplifikation af nukleinsyrer til diagnosticering af virusinfektioner gennem identifikation af virus i patientens biologiske prøve. Virksomheden har partnerskabsaftaler med QIAGEN om en diagnostisk løsning til påvisning af latent tuberkulose; TTP om udvikling af en molekylær Point-of-Care-løsning; og MeMed om lancering af en test, der skelner mellem virale og bakterielle infektioner. Virksomheden blev grundlagt i 1968 og har hovedkvarter i Saluggia, Italien.
| Navn | DiaSorin |
| CEO | Carlo Rosa |
| Hjemsted | Saluggia,
vc Italien |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 18.03.1996 |
| Medarbejdere | 3.272 |
Tickersymboler
| Børs | Symbol |
|---|---|
Mil | DIA.MI |
Pnk | DSRLF |
Frankfurt | 34D.F |
Düsseldorf | 34D.DU |
Milan | DIA.MI |
London | 0GZX.L |
München | 34D.MU |
Wien | DIAS.VI |